Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088049 · ClinicalTrials.gov registry record · Phase 4
Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 560
- Enrollment target
NCT00088049 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 560 participants.
The verdict
NCT00088049, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 560 participants
- Enrollment target
Study Summary
The purpose of the protocol is to evaluate the efficacy of olanzapine compared with Aripiprazole in patients with schizophrenia.
Interventions
- DRUG Olanzapine
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088049
The ClinicalTrials.gov registry entry for NCT00088049 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 560 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olanzapine is the first listed.
NCT00088049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088049 about?
NCT00088049 is a clinical study titled "Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia". The purpose of the protocol is to evaluate the efficacy of olanzapine compared with Aripiprazole in patients with schizophrenia.
What is the current status of trial NCT00088049?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 560 participants. The study started on 2003-10. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00088049?
The interventions under investigation include: Olanzapine (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00088049?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.